Corporate Information

• 23 Dec, 2022
  Spago Nanomedical avslutar avtal om likvididtetsgaranti
• 23 Dec, 2022
  Spago Nanomedical terminates liquidity guarantee
• 8 Dec, 2022
  Första patienten doserad i Spago Nanomedicals kliniska fas IIa-studie i endometrios
• 8 Dec, 2022
  First patient dosed in Spago Nanomedical’s endometriosis Phase IIa clinical study
• 6 Dec, 2022
  Spago Nanomedical inleder klinisk studie med SpagoPix i endometrios och avslutar SPAGOPIX-01
• 6 Dec, 2022
  Spago Nanomedical initiates clinical trial with SpagoPix in endometriosis and concludes SPAGOPIX-01
• 20 Oct, 2022
  Valberedning utsedd inför Spago Nanomedicals årsstämma 2023
• 20 Oct, 2022
  Nomination committee appointed for the 2023 Annual General Meeting in Spago Nanomedical
• 21 Sep, 2022
  Spago Nanomedical gets SpagoPix abstract accepted at breast cancer conference
• 21 Sep, 2022
  Spago Nanomedical får SpagoPix-abstract accepterat på bröstcancerkonferens